Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) (ATTACC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04372589|
Recruitment Status : Active, not recruiting
First Posted : May 4, 2020
Last Update Posted : February 1, 2021
|Condition or disease||Intervention/treatment||Phase|
|COVID-19 Pneumonia||Drug: Heparin||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1203 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Pragmatic, Bayesian adaptive randomized controlled trial|
|Masking:||None (Open Label)|
|Official Title:||Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)|
|Actual Study Start Date :||May 20, 2020|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||January 2021|
Experimental: Investigational arm
Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).
Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.
No Intervention: Control arm
Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
- Mortality and days free of organ support [ Time Frame: 21 days ]The primary endpoint in the trial is days alive and free of organ support at day 21. This endpoint is defined as the number of days that a patient is alive and free of organ support through the first 21 days after trial entry. Organ support is defined as receipt of invasive or non-invasive mechanical ventilation, high flow nasal oxygen (>30 L/min), vasopressor therapy, or ECMO support. Death at any time (including beyond 21 days) during the index hospital stay is assigned the worst possible score of -1.
- Arterial and venous thrombotic conditions [ Time Frame: 28 days and 90 days ]A composite endpoint of death, deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke collected during hospitalization or at 28 days and 90 days after enrollment (whichever is earlier).
- Intubation and mortality [ Time Frame: 30 days ]Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization: no invasive mechanical ventilation, invasive mechanical ventilation, or death.
- All-cause mortality [ Time Frame: 28 days and 90 days ]
- Intubation [ Time Frame: 30 days ]Invasive mechanical ventilation.
- Hospital-free days [ Time Frame: 28 days ]Days alive outside of the hospital through 28 days following randomization.
- Ventilator-free days [ Time Frame: 28 days ]Days alive not on a ventilator assessed at 28 days following randomization.
- Myocardial infarction [ Time Frame: 28 days and 90 days ]
- Ischaemic stroke [ Time Frame: 28 days and 90 days ]
- Venous thromboembolism [ Time Frame: 28 days and 90 days ]Symptomatic proximal venous thromboembolism (DVT or PE).
- Vasopressor-free days [ Time Frame: 28 days ]Days alive not on a vasopressor assessed at 28 days following randomization.
- Renal replacement free days [ Time Frame: 28 days ]Days alive not on renal replacement assessed at 28 days following randomization.
- Hospital re-admission [ Time Frame: 28 days ]Hospital re-admission within 28 days.
- Acute kidney injury [ Time Frame: Duration of study ]As defined by KDIGO criteria.
- Systemic arterial thrombosis or embolism [ Time Frame: 28 days and 90 days ]
- ECMO support [ Time Frame: Duration of study ]Use of extracorporeal membrane oxygenation (ECMO) support.
- Mechanical circuit thrombosis [ Time Frame: Duration of study ]Dialysis or ECMO.
- WHO ordinal scale [ Time Frame: 28 days ]Peak scale over 28 days, scale at 14 days, and proportion with improvement by at least 2 categories compared to enrollment, at 28 days.
- Major bleeding [ Time Frame: Intervention period (maximum 14 days) ]As defined by the International Society on Thrombosis and Haemostasis (ISTH).
- Heparin-induced thrombocytopenia (HIT) [ Time Frame: Intervention period (maximum 14 days) ]Laboratory-confirmed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04372589
|Principal Investigator:||Patrick R. Lawler, MD, MPH||Peter Munk Cardiac Centre/University Health Network|
|Principal Investigator:||Ewan C. Goligher, MD, PhD||University Health Network, Toronto|
|Principal Investigator:||Ryan Zarychanski, MD, MSc||University of Manitoba|